Skip to search formSkip to main contentSkip to account menu

canakinumab

Known as: immunoglobulin G1, anti-(human interleukin 1beta) (human clone ACZ885 heavy chain V region) 
A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab… 
National Institutes of Health

Related topics

Related topics

5 relations
1 ML canakinumab 150 MG/ML Injection [Ilaris]antigen bindingcanakinumab 180 MG Injection [Ilaris]

Narrower (1)

ACZ885

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome
The objective of this study was to report the benefit of a therapeutic approach consisting of intravenous (IV) continuous… 
Highly Cited
2019
Highly Cited
2019
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
Background and Objectives: Few studies have reported the drug retention rate (DRR) of biologic drugs in juvenile idiopathic… 
Highly Cited
2018
Highly Cited
2018
Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis
To assess performance of the 2016 macrophage activation syndrome (MAS) classification criteria for patients with systemic… 
Highly Cited
2016
Highly Cited
2016
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab
In pivotal trials, canakinumab has been shown to be effective in the treatment of systemic juvenile idiopathic arthritis (JIA… 
Highly Cited
2016
Highly Cited
2016
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study
This study aimed to evaluate the role of interleukin (IL)-1 inhibitors anakinra (ANA) and canakinumab (CAN) in the treatment of… 
Highly Cited
2015
Highly Cited
2015
Canakinumab in adults with steroid‐refractory pyoderma gangrenosum
Pyoderma gangrenosum (PG) is a rare, neutrophilic, ulcerative skin disease that is difficult to treat, especially when… 
Highly Cited
2013
Highly Cited
2013
Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis.
OBJECTIVE To report on the clinical response to canakinumab in a patient with sporadic nucleotide-binding oligomerization domain… 
Highly Cited
2012
Highly Cited
2012
Effect of anti‐IL‐1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo‐controlled trial
Evaluate anti‐interleukin‐1β (IL‐1β) antibody, canakinumab, in patients with type 2 diabetes and impaired glucose tolerance (IGT… 
Highly Cited
2012
Highly Cited
2012
Marketed therapeutic antibodies compendium
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as… 
Highly Cited
2011
Highly Cited
2011
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
BackgroundCanakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)